Bris­tol My­ers touts up­beat da­ta for its block­buster heart drug can­di­date

While the FDA stretch­es out its re­view for Bris­tol My­ers Squibb’s mava­camten, the phar­ma gi­ant isn’t wast­ing any time bol­ster­ing en­thu­si­asm for the heart drug.

Over the week­end Bris­tol My­ers pre­sent­ed two ma­jor sets of da­ta at the Amer­i­can Col­lege of Car­di­ol­o­gy’s an­nu­al con­fer­ence for mava­camten — which it picked up in the $13 bil­lion MyoKar­dia ac­qui­si­tion. The take-home mes­sage: Not on­ly is the car­diac myosin in­hibitor work­ing well in tri­als, but it should al­so prove to be “clin­i­cal­ly mean­ing­ful.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA